(vianews) - the market ended the session with guerbet (gbt.pa) jumping 11.99% to €34.10 on friday, following the last session's upward trend. cac 40 fell 0.34% to €8,151.92, following the last session's upward trend on what was a somewhat down trend exchanging session today.
guerbet's last close was €30.45, 31.25% higher than its 52-week high of €23.20.
about guerbet
guerbet sa engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. the company offers optiray and xenetix, which are non-ionic monomeric and iodinated contrast agents; telebrix gastro, a meglumine ioxitalamate solution; conray, an iothalamate meglumine injection; micropaque/microtrast, a diagnostic imaging interconnected solution; dotarem, a gadoteric acid-gadoterate meglumine, and artirem, a gadoteric acid that acts as a contrast agent for mri, as well as prefilled syringes, injectors, accessories, and consumables for mri, ct, and cath lab. it also provides digital solutions, such as contrast&care, an injection management solution; dose&care, an x-ray dose management solution; and icobrain, a cloud-based ai solution to quantify disease-specific brain structures for acute and chronic neurological conditions on mr and ct, as well as optiprotect services. in addition, the company provides products for interventional radiology, including lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; patent blue v, a blue dye; axessio, a peripheral micro guidewire; and sequre and drakon, which are microcatheters. further, it offers hydra vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. the company was incorporated in 1926 and is headquartered in villepinte, france.
earnings per share
as for profitability, guerbet has a trailing twelve months eps of €-3.35.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -10.79%.
dividend yield
according to morningstar, inc., the next dividend payment is on jun 29, 2023, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 2.97%.
more news about guerbet (gbt.pa).